Logo

Exelixis Reports 3Q Revenues Up

Nov 05, 2003

NEW YORK, Nov. 5, (GenomeWeb News) - South San Francisco-based Exelixis reported $12.4 million in revenues for the third quarter ending Sept. 30, up over revenues of $10.4 million for the same period in 2002.

 

The company reported a net loss of approximately $25 million, up over a net loss of $23 million for the third quarter in 2002.

 

The company had cash, cash equivalents, short-term investments, and restricted cash of approximately $219 million as of Sept. 30, compared to $222 million at December 31, 2002.

 

Research and development expenses for the quarter ended September 30, 2003 were $32 million compared to $29 million for the same quarter in 2002.

Breaking News
The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.